<DOC>
	<DOC>NCT00618046</DOC>
	<brief_summary>The objective of this study was to assess bioequivalence of a potential generic 600 mb oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, following a single 600 mg dose, administered with food.</brief_summary>
	<brief_title>Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>No clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results at screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with any known enzyme altering drugs. History of allergic or adverse response to oxcarbazepine or any other comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>